Imagine your body has its own built-in security system that can fight germs, but sometimes it's just asleep. This project creates a 'wake-up call' in the form of a special drug that tells your immune system to produce its own natural germ-killers. Instead of using traditional antibiotics that bacteria can learn to beat, this method helps your own body win the fight.
Traditional antibiotics are failing as pathogens evolve into pan-drug resistant strains, leading to millions of deaths. Developing new antibiotics is too slow and expensive to keep pace with these mutations.
A library of over 100 Immune System Inducer (ISI) compounds and a nanotech-based drug delivery system for gastrointestinal targets.
If you are a drug development firm dealing with the slow and expensive process of creating new antibiotics — this project developed a class of Immune System Inducers (ISIs) that stimulate natural defenses. This could potentially reduce the global disease burden by 96.84 million DALYs.
If you are a nanomedicine specialist dealing with poor drug delivery in the gut — this project developed a nanotech-based drug delivery system for gastrointestinal infections. This allows the therapy to reach the target site effectively to combat priority-1 pathogens.
If you are a hospital network dealing with pan-drug resistant strains that threaten patient lives — this project developed a therapy targeting 13 of the most dangerous infections. This approach aims to save more than 4 million lives worldwide.
Based on available project data, commercialization could result in a long-term cost reduction impact of €107 billion by reducing the burden of antibiotic development.
Based on available project data, the project is currently in the preclinical validation stage (in vitro and in vivo) and is being prepared for clinical validation.
Based on available project data, the project has synthesized over 100 novel compounds, but specific licensing or patent details are not provided in the summary.
The project period runs from 2023-05-01 to 2027-04-30, with the goal of being prepared for clinical validation upon completion.
The therapy is designed as a new class of Immune System Inducers (ISIs) that can be delivered via nanotechnology, specifically targeting gastrointestinal infections and IBD.
The consortium is highly balanced for commercial translation, featuring 18 partners across 10 countries. With an industry ratio of 44% (8 industry partners, including 6 SMEs), there is a strong bridge between the 6 universities and the market. This structure suggests a high priority on moving the 100+ synthesized compounds from the lab into a viable medical product.
Contact HASKOLI ISLANDS (IS)
Contact us to explore licensing opportunities for these Immune System Inducers.
